key: cord-0814904-gs34ne2m
authors: Liu, Yuzhi; Liang, Chengyuan; Xin, Liang; Ren, Xiaodong; Tian, Lei; Ju, Xingke; Li, Han; Wang, Yongbo; Zhao, Qianqian; Liu, Hong; Cao, Wenqiang; Xie, Xiaolin; Zhang, Dezhu; Wang, Yu; Jian, Yanlin
title: The Development of Coronavirus 3C-Like Protease (3CL(pro)) Inhibitors from 2010 to 2020
date: 2020-08-06
journal: Eur J Med Chem
DOI: 10.1016/j.ejmech.2020.112711
sha: 420fce8bbe6967373ce3140c24c58a46ca8bb923
doc_id: 814904
cord_uid: gs34ne2m

This review fully describes the coronavirus 3CL(pro) peptidomimetic inhibitors and nonpeptidic small molecule inhibitors developed from 2010 to 2020. Specifically, the structural characteristics, binding modes and SARs of these 3CL(pro) inhibitors are expounded in detail by division into two categories: peptidomimetic inhibitors mainly utilize electrophilic warhead groups to covalently bind the 3CL(pro) Cys145 residue and thereby achieve irreversible inhibition effects, whereas nonpeptidic small molecule inhibitors mainly interact with residues in the S1’, S1, S2 and S4 pockets via hydrogen bonds, hydrophobic bonds and van der Waals forces. Based on the emerging PROTAC technology and the existing 3CL(pro) inhibitors, 3CL(pro) PROTAC degraders are hypothesised to be next-generation anti-coronavirus drugs.

coronavirus, to yield 16 nsps (Fig 1) [26, 27] . 3CL pro contains three domains [28, 29] , including a non-classical Cys-His catalytic dyad (Cys145 and His41) in the gap between domains I and II [30] ; can specifically recognize the 11 cleavage sites of nsp4~nsp16; and exhibits self-hydrolytic cleavage activity [31, 32] . These functional nsps (nsp4~nsp16) released by cleavage with 3CL pro are responsible for viral genome replication and transcription, and nsp4~nsp16 also play roles in other important viral life processes, such as protein translation, cleavage, and modification and nucleic acid synthesis [25, 33] . Therefore, inhibition of 3CL pro can effectively block viral RNA replication and transcription and further block viral proliferation. In addition, 3CL pro is highly conserved among the known coronavirus species, and several common features are shared among the different coronavirus 3CL pro substrates. From the N terminus to the C terminus, the amino acids in the substrates are numbered -P4-P3-P2-P1↓P1'-P2'-P3'-, and the cleavage site is located between P1 and P1' [34, 35] . In particular, a Gln residue is almost always required at the P1 position of the substrates. Nevertheless, amino acid sequence alignments indicate that the similarity of the 3CL pro of SARS-CoV-2 and SARS-CoV can be as high as 96.1% [36, 37] . Only 12 of the 306 residues differ, namely, T35V, A46S, S65N, L86V, R88K, S94A, H134F, K180N, L202V, A267S, T285A and I286L, and these different amino acid residues are 3CL pro inactive sites [38, 39] . Further sequence comparisons have revealed that the 3CL pro of the three coronaviruses SARS-CoV-2, SARS-CoV, and MERS-CoV exhibit a high degree of structural similarity and conservation (Fig 2) [40]. These findings indicate that 3CL pro could be used as a homologous target for the development of anti-coronavirus drugs that can inhibit the proliferation of various coronaviruses. 

Structurally, 3CL pro inhibitors can be classified as peptoids and nonpeptidomimetics, and the mechanism of action of peptide inhibitors includes two J o u r n a l P r e -p r o o f steps. Peptidomimetics that mimic natural peptide substrates initially bind to 3CL pro and form a noncovalent complex, and the warhead group, which is spatially very close to the catalytic residue of the target protein, undergoes nucleophilic attack to catalyse the formation of covalent bonds involving cystein [41, 42] . These warheads mainly contain Michael receptors [43, 44] , aldehydes [45] and different types of ketones (see Fig 3 and Table 1 ) [46] [47] [48] , which covalently bind to the Cys145 residue in the 3CL pro S1' pocket to exert an inhibitory effect. Among these peptidomimetic inhibitors, aldehyde compounds 11 and 12 and α-ketoamide compounds 25-27 showed good inhibitory activity against the current SARS-CoV-2. Compounds, which are novel inhibitors designed and synthesized for SARS-CoV-2 3CL pro by Hong Liu and colleagues [57] , exhibit excellent inhibitory activity against SARS-CoV-2 3CL pro (11: IC 50 =0.053±0.005 µM, 12:

detailed diagram of the interaction between compound 11 and SARS-CoV-2 3CL pro shows that the aldehyde carbonyl of 11 and the catalytic site Cys145 of SARS-CoV-2 3CL pro form a standard C-S covalent bond (Fig 4-A) . The oxygen atom of the aldehyde group forms a hydrogen bond with the backbone of the Cys145 residue at the S1' site, which is crucial for stabilizing the binding conformation. The (S)-γ-lactam ring at P1 is compatible with the S1 site, and the oxygen atom of the (S)-γ-lactam group forms a hydrogen bond with the His163 side chain, the main chain of Phe140 and the side chain of Glu166 and forms a hydrogen bond with the NH group of the (S)-γ-lactam ring. The cyclohexyl part at the P2 position can be inserted into the S2 position and stacks with the imidazole ring of His41. The indole group at the P3 position is exposed to the solvent (S4 site) and forms a hydrogen bond with Glu166. Interestingly, multiple water molecules (named W1-W6) play important roles in the binding of 11: W1 interacts with the amide bond of 11 through hydrogen bonding, whereas W2-W6 forms a few hydrogen bonds with the aldehyde group of 11 and the residues Asn142, Gly143, Thr26, Thr25, His41 and Cys44, which contribute to the stability of the binding pocket of 11. The binding mode of compound 12 is very similar to that of 11 (Fig 4-B) . The difference in their binding modes might be due to bond by other cellular proteases. In addition, to enhance the solubility of 24 in plasma, the hydrophobic cinnamyl was replaced by a low-hydrophobicity Boc group (Fig 5, red circle), which produced 25. Moreover, the cyclohexyl at P2 of 25 was substituted with the smaller cyclopropyl (Fig 5, Inspired by the interaction of peptide inhibitor 28 between S1 and S2 of SARS-CoV 3CL pro , Shimamoto Yasuhiro et al. [60] designed and synthesized a series of competitive SARS-CoV 3CL pro inhibitors (compounds 29a-29d, Fig 6) with a decahydroisoquinoline fused ring scaffold. All synthetic decahydroquinoline inhibitors exhibited moderate to significant inhibition of SARS 3CL pro . According to X-ray crystallography (PDB code: 4TWY, Fig 7) , the fused ring structure of dehydroquinoline occupies most of the space in the S2 pocket. X-ray crystallography clearly showed that the (4aR, 8aS) isomer is more potent than the (4aS, 8aR) isomer. Additionally, Kouji Ohnishi et al. [62] introduced a nonprime site substituent at the 4-position carbon of the decahydroisoquinolin skeleton to yield the nonpeptidic inhibitor 38, which exhibits moderate but enhanced inhibitory activity against R188I SARS 3CL pro (IC 50 =26 µM). The results indicated significantly increased affinity between 38 and SARS 3CL pro at the S3 to S4 pockets. µM) exhibited compelling inhibitory activity against SARS-CoV 3CL pro . The X-ray crystal structure of (R)-40a combined with SARS-CoV 3CL pro (Fig 11) demonstrated that (R)-40a preferentially occupied the S1'-S3 3CL pro subpockets. According to the identified binding mode, the tert-butyl amide occupies the S3 pocket, the tert-butyl anilido group occupies a deep S2 pocket, and the 3-pyridyl group occupies the S1 pocket. To further clarify the structure-activity relationship (SAR) of lead compound 40a, the P1-P3 framework was maintained consistently, while a library of five-membered aromatic heterocycles was synthesized through alterations in the P1' position ( Table 2, 41a-41f). Among the resulting compounds, imidazole-substituted (41c, IC 50 =6 µM) and 5-chlorofuran-substituted (41e, IC 50 =5.2 µM) analogues were found to be the most potent. A subsequent study of P1 replacements was performed to identify J o u r n a l P r e -p r o o f alternative hydrogen bond acceptor groups that might engage His163 while retaining the 2-furyl amide P1' group. Among the six-membered π-excessive heterocycles examined (42a-42c), pyridazine (42a) and pyrazine (42b) were well tolerated.

Furthermore, chiral stationary-phase supercritical fluid chromatography (SFC) was applied to separate 40a enantiomers (Fig 10-B) , and highly specific inhibition was obtained with the single stereoisomer (R)-40a (ML188), which exhibited an IC 50 of 1.5±0.3 µM. According to X-ray crystallography (PDB code: 4MDS, Fig 12) , As a promising hit, the template compound 43 has been subjected to intense derivatization, including P1 modification, P2-P1' exploration and P3 truncation (Fig   13) . Table 3) . 

Based on an analysis of the optimization of the lead GC376 (52), addition of an aldehyde bisulphite at the P1' position is necessary for the reaction with the active site Cys148 to generate tetrahedral hemithioacetal. Moreover, the γ-lactam ring at the P1 position and the Leu side chain at the P2 position should be retained and might occupy the S1 and S2 hydrophobic pockets, respectively. Additionally, extending the benzyloxy "cap" to the chlorine-substituted phenylethanol fragment yields GC813 (53) , and its lower IC 50 value can be attributed to an extended conformation and might orient the phenyl ring towards the hydrophobic S4 pocket. As a common privileged scaffold in drug design and discovery, the piperidine moiety is a good design element that can exhibit favourable interactions with numerous classes of proteins, which would result in optimal pharmacological activity and PK properties [65] . Thus, introducing the high-affinity piperidine moiety into the peptoid scaffold yields a series of structurally novel inhibitors (Table 4, 54a-54f) . The piperidine-based design strategy is an effective tactic for rendering a dipeptidyl inhibitor capable of engaging in optimal binding interactions with all four S1-S4 subsites, and the resulting inhibitors have a lower molecular weight and a reduced peptidyl character compared with the tetrapeptidyl inhibitor, which is expected to display enhanced solubility and J o u r n a l P r e -p r o o f PK lability. Gratifyingly, 54b and 54d, which are representative aldehyde bisulphite compounds, display potent MERS-CoV inhibitory activities with low cytotoxicity (CC 50 >100 µM). Unsymmetrical aromatic disulphide compounds are a class of inhibitors that exert significant inhibitory effects on SARS 3CL pro [66] . These new chemical entities display excellent IC 50 values in the range of 0.516 to 5.954 µM (Fig 14, form intermolecular hydrogen bonds with 55 (Fig 15) . 

To [67, 68] . First, imidazole, cyclohexyl, and hydroxyl groups, which were previously reported in the literature and exhibit potent biological activity, were linked to L-serine for the design of serine derivatives (61, 62) , as shown in Fig 16. However, compared with peptide inhibitor 83, these optimized groups did not provide good coverage of the substrate recognition pocket of 3CL pro (PDB code: 3AW1), and the different binding modes of peptide inhibitors and non-peptide inhibitors with 3CL pro led to changes in the interactions between these groups and the corresponding pocket [69] . It was hypothesized that the cyclohexyl group would occupy the S2 pocket of 3CL pro , but contrary to expectations, molecular mechanics calculations and docking simulations indicated that the cyclohexyl group of serine derivatives (61, 62) must occupy the S1 pocket of 3CL pro . Thus, the imidazole and hydroxyl groups of 61 and 62, which are expected to interact with the S1 and S4 pockets, were not effective and thereby reduced the interaction between the inhibitor and 3CL pro . In addition, Bai's inhibitor 63 is located deep inside the S'1, S1

and S2 pockets and exhibits appropriate cinnamoyl functionalities [70] . Therefore, benzoyl and aniline groups were used for molecular docking with serine derivatives to obtain 64. In addition, reasonable structural transformations of the serine derivative and hybrids constructed with other functionalities were investigated. Virtual screening using GOLD software indicated that N-cinnamoyl derivatives with benzoate, such as 64 and 65, are suitable substructures. (Fig 17) . In addition, cyclohexyl rings are essential to the P1 function of PIS scaffolds, whereas the cinnamyl functional group at P4 can effectively maintain the inhibitory strength. Further SAR studies have shown that the pharmacophore phenyl at R 3 (74a vs74b) and a carboxylate at either R 1 or R 4 (74c vs 74d) are essential for the activity (Fig 18) .

Because the modification of rings A and B is tolerated well, the D ring can be further altered to enhance the activity of the compounds.

Another series of 2-(benzylthio)-6-oxo-4-phenyl-1,6-dihydropyrimidines (75a-75f) also showed encouraging results as new anti-SARS hits [73] . The cytotoxicity of the test compounds was assessed using the MTT assay, and all the compounds were devoid of cytotoxicity. Further SAR studies revealed that compound 75c, which has a nitro at the C-4 position, is the most potent inhibitor of SARS-CoV 3CL pro (IC 50 =6.1 µM). A moderately electron-withdrawing substituent at R l , such as chloro, in compounds 75c and 75d improved the inhibitory activity compared with electron-donating groups, such as methyl and methoxy groups (as shown in Table 5 ). µM, 73 µM and 47 µM, respectively (Fig 19) . In addition, 78 exhibited competitive inhibition towards 3CL pro , with a Ki value of 25 µM. According to the results from a J o u r n a l P r e -p r o o f docking analysis, the galloyl acyl moiety at the 3-OH position of compound 78, which occupies the S1 pocket, is essential for inhibitory activity against 3CL pro [74] . A series of inhibitors were isolated and purified from the leaves of Torreya nucifera (Fig 19) .

According to a preliminary screen, the biflavone amentoflavone (79) Another series of chalcones (Fig 19, 83-85 ) isolated from Angelica keiskei were evaluated in terms of their anti-SARS 3CL pro activity. Chalcone 84, which contains perhydroxyl groups, exhibited the most potent inhibitory activity against 3CL pro , with an IC 50 value of 11.4 µM. A detailed ligand-protein mechanistic analysis indicated that the chalcones exhibited competitive inhibition with SARS-CoV 3CL pro [76] .

Previous studies have shown that isatin and its derivatives have a wide range of antiviral and antibacterial activities [77] [78] [79] , including anti-HIV virus [80, 81] ,

anti-hepatitis C virus (HCV) [82] , anti-Mycobacterium tuberculosis and anti-pathogenic activities [83, 84] . In addition, isatin derivatives are good candidates for the development of anti-coronavirus drugs [85] . For anti-coronavirus drug discovery, a series of synthetic 5-sulphonyl isatin derivatives (86) (87) (88) (89) (90) (91) (92) were reported as noncovalent SARS M pro inhibitors [86] . These isatin derivatives inhibited SARS-CoV [88] . Dihydrocelastrol (104) was synthesized by hydrogenation with a palladium catalyst, but its 3CL pro inhibitory activity against SARS 3CL pro was relatively weak. Further SAR research indicated that a quinone-methide moiety in the A ring and a more hydrophobic E ring could promote inhibitory activity against 3CL pro . 

As the cases of SARS-CoV-2 infections continue to rise, the need for the Herein, the structural characteristics, binding modes and SARs of recent coronavirus 3CL pro inhibitors are comprehensively described. The warhead groups of peptidomimetic inhibitors mainly include aldehydes, ketones and different types of Michael receptors. These covalent irreversible inhibitors mainly utilize warhead functional groups to covalently bond with Cys145 residues in the 3CL pro S1' pocket and thereby exert relatively durable inhibitory effects. Published studies have shown that covalent irreversible 3CL pro inhibitors exhibit significantly improved antivirus activity, and some inhibitors can even achieve effects at nanomolar levels. However, covalent inhibitors exhibit potential off-target effects and toxic side effects. Although recent studies on peptidomimetic inhibitors are fewer than those that investigated nonpeptidic inhibitors, aldehyde compounds 11 and 12 and α-ketoamide compounds (25) (26) (27) , which are among the recently reported peptidomimetic 3CL pro inhibitors, exhibit excellent inhibitory activity against SARS-CoV-2. Inhibitor 11 is one of the most effective inhibitors among the aldehyde peptide series. Thus, the toxicity of inhibitor 11 over a 7-day period has been studied at different doses, specifically at dosing levels of 2, 6, and 18 mg/kg on SD rats and at a dose range of 10-40 mg/kg on beagle dogs, and all the tested animals showed significant toxicity after the inhibitor was administered once a day (QD) via intravenous drip. Therefore, 11 might be a good candidate for further clinical research on COVID-19. Coincidentally, the PK characteristics of compound 26 indicated obvious lung affinity, and this compound is suitable for administration via inhalation. Therefore, the pyridone-containing compound 26 might become another lead for further COVID-19 pandemic research.

Correspondingly, noncovalent reversible 3CL pro inhibitors mainly exhibit weak reversible binding (such as hydrogen bonds, van der Waals forces, and hydrophobic forces) with the amino acid residues in the S1, S2, and S4 pockets, which sometimes includes the catalytically active Cys145 in the S1' pocket. This weak reversible binding could result in avoidance of the off-target risk and toxicity of irreversible inhibitors, and thus, these inhibitors might be suitable for long-term administration.

Among the nonpeptidic reversible inhibitors, 55-59, which contain a piperidine moiety, and 54a-54f, which contain unsymmetrical aromatic disulphides, exhibit excellent inhibitory activity. Some natural products and derivatives, such as isatin [89] , flavonoids, and tanshinone, might also be good candidates for the development of anti-coronavirus drugs. Specifically, 46a, 54a, 74d and 75c are noncovalent SARS-CoV 3CL pro inhibitors with a moderate molecular weight and good antiviral activity and can potentially be utilized as lead templates for further drug design and screening.

However, 3CL pro noncovalent inhibitors also have some shortcomings, such as drug effects that are not strong and/or durable, which means that these noncovalent inhibitors would need to be administered at high dosages or multiple times.

Noncovalent inhibitors can also result in the emergence of resistance after long-term administration. Based on a review of the advantages and disadvantages of both covalent and noncovalent inhibitors of 3CL pro , we recommend that reversible covalent inhibitors of 3CL pro constitute a new research direction. Specifically, the Michael warhead can be replaced by cyano (or trifluoromethyl), which might result in the formation of a reversible covalent bond with the Cys145 residue, which is unique to the coronavirus 3CL pro S1' pocket, and this binding can potentially reduce the "off-target" risk and toxic side effects while enhancing the efficacy [90] [91] [92] [93] . Further analyses of previous studies on 3CL pro inhibitors in association with the booming research on proteolysis-targeting chimaeras (PROTACs) [94, 95] have led to the emergence of the following drug development ideologies. PROTAC technology can be used in the design of anti-coronavirus drugs that induce the intracellular J o u r n a l P r e -p r o o f degradation of functional nsps of exogenous viruses. The principle of PROTAC technology involves the use of a bifunctional small molecule to link the target protein and the E3 ligase in the cell such that the target protein is ubiquitinated, and the ubiquitinated protein is then recognized by the proteasome, which leads to degradation of the target protein [96] . To date, various endogenous proteins, such as BTK, PARP1, HDAC6, AR, ER, BET, BRD4, BRD9, RIPK2, TBK1, Sirt2, CDK9, p38α, pirin, c-Met, EGFR, FAK, and FLT3, have been reportedly degraded using PROTAC technology [97] [98] [99] . However, the application of PROTAC technology for the degradation of foreign proteins (such as viral proteins) remains in its infancy. To date, only the NS3/4A protease degrader DGY-08-097 of HCV has been reported, and its antiviral activity and resistance characteristics are significantly superior to those of the traditional drug telaprevir [100] . Thus, we propose that the existing 3CL pro inhibitors can be combined with PROTAC technology to develop coronavirus 3CL pro PROTACs. These PROTAC degraders could exhibit the advantages of both occupancy-driven 3CL pro inhibitors and those of event-driven PROTACs: low-dose exposure would result in multiple rounds of 3CL pro degradation and would avoid the intracellular accumulation of 3CL pro in infected cells. These procedures would completely block the biological function of coronavirus 3CL pro and its downstream viral proteins and would therefore inhibit the assembly and replication of the coronavirus in infected cells (shown in Fig 20) . Reversible covalent PROTACs for 3CL pro have been designed and synthesized in our laboratory for further screening, and we expect that these inhibitors will overcome the shortcomings of traditional 3CL pro inhibitors and take advantage of the degradation effects of PROTACs. 

A new coronavirus associated with human respiratory disease in China

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet

Origin and evolution of pathogenic coronaviruses

Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans

Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors

Recent Aspects on the Pathogenesis Mechanism, Animal Models and Novel Therapeutic Interventions for Middle East Respiratory Syndrome Coronavirus Infections

Current treatment options and the role of peptides as J o u r n a l P r e -p r o o f potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review

Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission

Origin and evolution of pathogenic coronaviruses

The Genome sequence of the SARS-associated coronavirus

Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Identification of novel J o u r n a l P r e -p r o o f inhibitors of the SARS coronavirus main protease 3CLpro

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus

Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase

Activation and maturation of SARS-CoV main protease

The substrate specificity of SARS coronavirus 3C-like proteinase

Drug design targeting the main protease, the Achilles' heel of coronaviruses

Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery

Potential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study

Mechanism of the maturation process of SARS-CoV 3CL protease

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain

Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening, bioRxiv

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

A new J o u r n a l P r e -p r o o f coronavirus associated with human respiratory disease in China

The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase

Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease

Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease

Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors

Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease

Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus

Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors

Synthesis of glutamic acid and glutamine peptides possessing a trifluoromethyl ketone group as SARS-CoV 3CL protease inhibitors

Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters

Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors

Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor

Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease

Synthesis and evaluation of keto-glutamine analogues as syndrome 3CLpro

Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies

Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study

α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design

Structure-Based Design

Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease, bioRxiv

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy

Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors

Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor

Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor

Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding

Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents

Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element

Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study

Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor

Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease

Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors

Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors

Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors

Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors

Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease

Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition

Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV

Isatin derivatives and their anti-bacterial activities

Synthesis and Antimicrobial Activity of 5-(morpholinosulfonyl)isatin Derivatives Incorporating a Thiazole Moiety

Computational evaluation and experimental in vitro antibacterial, antifungal and antiviral activity of bis-Schiff bases of isatin and its derivatives

Isatin thiazoline hybrids as dual inhibitors of HIV-1 reverse transcriptase

Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6

Vitro Antiviral Activity of some Novel Isatin Derivatives against HCV and SARS-CoV Viruses

Design, synthesis and anti-mycobacterial activity evaluation of benzofuran-isatin hybrids

Synthesis, antitubercular and anticancer activity of new Baylis-Hillman adduct-derived N-cinnamyl-substituted isatin derivatives, Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents

Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors

Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors

Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases

SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii

Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors

Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR

Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles

Electrophilic fragment-based design of reversible covalent kinase inhibitors

Design of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and Computational Analysis

Induced protein degradation: an emerging drug discovery paradigm

Targeted protein degradation: expanding the toolbox

PROTACs: great opportunities for academia and industry

Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase

Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer

Structural basis of PROTAC cooperative recognition for selective protein degradation

This work was supported by the National Natural Science Foundation of China